Cargando…

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review

The determination of radioiodine remnant ablation (RRA) dosage in post-operation thyroid residual tissues resection has been largely subject of discussion, yet no concise conclusion is released through systematic review studies. In this study, we conducted a systematic review of comparative experime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ansari, Mojtaba, Rezaei Tavirani, Mostafa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Brieflands 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420215/ https://www.ncbi.nlm.nih.gov/pubmed/36060901 http://dx.doi.org/10.5812/ijpr-123825

Ejemplares similares

Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
por: Soyluoglu, Selin, et al.
Publicado: (2023)

Radioiodine Remnant Ablation: A Critical Review
por: Bal, Chandra Sekhar, et al.
Publicado: (2015)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
por: Ha, Seunggyun, et al.
Publicado: (2015)

Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
por: Krčálová, Eva, et al.
Publicado: (2020)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
por: Pitoia, Fabián, et al.
Publicado: (2012)

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010
por: Rachinsky, I., et al.
Publicado: (2016)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
por: Lv, Rong-Bin, et al.
Publicado: (2017)

Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect
por: Makarewicz, Jacek, et al.
Publicado: (2010)

Strong Neck Accumulation of (131)I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone
por: Enomoto, Keisuke, et al.
Publicado: (2015)

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment
por: Bal, Chandrasekhar, et al.
Publicado: (2015)

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
por: Xiao, Juan, et al.
Publicado: (2021)

Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
por: Jin, Meihua, et al.
Publicado: (2020)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Pak, Kyoungjune, et al.
Publicado: (2014)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
por: Hammes, Jochen, et al.
Publicado: (2018)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Biondi, Bernadette, et al.
Publicado: (2009)

Heath-related quality of life in thyroid cancer patients following radioiodine ablation
por: Taïeb, David, et al.
Publicado: (2011)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
por: Alsaud, Arwa, et al.
Publicado: (2020)

Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis
por: Gómez-Pérez, Ana María, et al.
Publicado: (2020)

Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis
por: Rojas, Tatiana, et al.
Publicado: (2021)

Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma
por: Li, Fuxin, et al.
Publicado: (2020)

Post-Surgical Ablative or Adjuvant Radioiodine Therapy Has No Impact on Outcome in 1–4 cm Differentiated Thyroid Cancers without Extrathyroidal Extension
por: De Leo, Simone, et al.
Publicado: (2021)

Evaluation of Diagnostic Value of SPECT/CT Imaging in Post-radioiodine Therapy in Thyroid Cancer
por: Al Hatmi, Asma, et al.
Publicado: (2022)

Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review
por: Yoo, J., et al.
Publicado: (2009)

Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer
por: Upadhyaya, Arun, et al.
Publicado: (2017)

Thyrotoxicosis and radioiodine therapy: Does the dose matter?
por: Collier, Andrew
Publicado: (2012)

The EANM guideline on radioiodine therapy of benign thyroid disease
por: Campennì, Alfredo, et al.
Publicado: (2023)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
por: Christina, Edelyn, et al.
Publicado: (2023)

The Effect of High Dose Radioiodine Therapy on Formation of Radiation Retinopathy During Thyroid Cancer Treatment
por: Kaçar Güveli, Tülay, et al.
Publicado: (2014)

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy
por: Mishra, Ayush, et al.
Publicado: (2023)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
por: Maghsoomi, Zohreh, et al.
Publicado: (2021)

Recombinant TSH Stimulated Remnant Ablation Therapy in Thyroid Cancer: The Success Rate Depends on the Definition of Ablation Success—An Observational Study
por: van der Horst-Schrivers, Anouk N. A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b7d2eqnqk4cvovo5cnlbrd4jfi